Adjuvant therapy for stomach cancer with special markers
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment plan after surgery for stomach cancer that shows certain markers, to reduce the chance of the cancer coming back. It includes drugs that help your immune system fight cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had surgery to remove stomach or gastroesophageal junction cancer, and it was stage II or III (2 or 3).
- You have not had chemotherapy, radiation, or other cancer treatments for this cancer before surgery.
- Your cancer test shows a high PD-L1 CPS score (5 or higher), or it is EBV-positive, or dMMR.
- You are generally in good health, able to do daily activities, and your blood and heart/liver tests are within certain limits.
- You are willing to use birth control during and for 3 months after the trial, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted radiation treatment during surgery to the usual combination of immunotherapy and chemotherapy helps people with advanced stomach cancer before they have surgery to remove the tumor. The goal is to see if this extra treatment can improve outcomes.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial studies which follow-up treatment is better for people with stomach or gastroesophageal junction cancer who had complete response to chemotherapy and immunotherapy before surgery, and whose tumor was completely removed. The goal is to reduce the chance of cancer coming back.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This trial tests whether adding immunotherapy to chemotherapy after surgery for stomach or gastroesophageal junction cancer helps prevent the cancer from coming back. It is for people whose cancer is HER2-negative and who have had the tumor completely removed.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.